Vitamin B12 Deficiency and Impact on MRI Morphometrics: Association Between Cognitive Impairment and Neuroimaging Findings

Author(s):  
Min-Chien Tu ◽  
Yen-Hsuan Hsu ◽  
Chung-Ping Lo ◽  
Ching-Feng Huang
2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Keitaro Kimoto ◽  
Bunta Shibasaki ◽  
Norio Tamura ◽  
Yuki Takahashi ◽  
Mizuki Maehara ◽  
...  

2012 ◽  
Vol 24 (4) ◽  
pp. 541-556 ◽  
Author(s):  
Eileen Moore ◽  
Alastair Mander ◽  
David Ames ◽  
Ross Carne ◽  
Kerrie Sanders ◽  
...  

ABSTRACTBackground: This review examines the associations between low vitamin B12 levels, neurodegenerative disease, and cognitive impairment. The potential impact of comorbidities and medications associated with vitamin B12 derangements were also investigated. In addition, we reviewed the evidence as to whether vitamin B12 therapy is efficacious for cognitive impairment and dementia.Methods: A systematic literature search identified 43 studies investigating the association of vitamin B12 and cognitive impairment or dementia. Seventeen studies reported on the efficacy of vitamin B12 therapy for these conditions.Results: Vitamin B12 levels in the subclinical low-normal range (<250 ρmol/L) are associated with Alzheimer's disease, vascular dementia, and Parkinson's disease. Vegetarianism and metformin use contribute to depressed vitamin B12 levels and may independently increase the risk for cognitive impairment. Vitamin B12 deficiency (<150 ρmol/L) is associated with cognitive impairment. Vitamin B12 supplements administered orally or parenterally at high dose (1 mg daily) were effective in correcting biochemical deficiency, but improved cognition only in patients with pre-existing vitamin B12 deficiency (serum vitamin B12 levels <150 ρmol/L or serum homocysteine levels >19.9 μmol/L).Conclusion: Low serum vitamin B12 levels are associated with neurodegenerative disease and cognitive impairment. There is a small subset of dementias that are reversible with vitamin B12 therapy and this treatment is inexpensive and safe. Vitamin B12 therapy does not improve cognition in patients without pre-existing deficiency. There is a need for large, well-resourced clinical trials to close the gaps in our current understanding of the nature of the associations of vitamin B12 insufficiency and neurodegenerative disease.


2019 ◽  
Vol 15 ◽  
pp. P586-P586
Author(s):  
Asako Ueno ◽  
Tadanori Hamano ◽  
Soichi Enomoto ◽  
Norimichi Shirafuji ◽  
Miwako Nagata ◽  
...  

2016 ◽  
Vol 06 (06) ◽  
Author(s):  
Min Chien Tu ◽  
Chung Ping Lo ◽  
Ching Yuan Chen

2011 ◽  
Vol 57 (10) ◽  
pp. 1436-1443 ◽  
Author(s):  
Dorte L Lildballe ◽  
Sergey Fedosov ◽  
Paul Sherliker ◽  
Harold Hin ◽  
Robert Clarke ◽  
...  

BACKGROUND Low vitamin B12 concentrations have been associated with higher risks of cognitive impairment, but whether these associations are causal is uncertain. The associations of cognitive impairment with combinations of vitamin B12, holotranscobalamin, methylmalonic acid, and total homocysteine, and with the vitamin B12 transport proteins transcobalamin and haptocorrin, have not been previously studied. METHODS We performed a population-based cross-sectional study of 839 people 75 years old or older. We examined the association of cognitive function as measured by mini–mental state examination scores, with markers of vitamin B12 status. Spearman correlations as well as multivariate-adjusted odds ratios and 95% CIs for cognitive impairment were calculated for extreme thirds of serum concentrations of vitamin B12, holotranscobalamin, methylmalonic acid, total homocysteine, combination of these markers in a wellness score, heaptocorrin, and transcobalamin for all data and with B12 analogs in a nested case-control study. RESULTS Cognitive impairment was significantly associated with low vitamin B12 [odds ratio 2.3 (95% CI 1.2–4.5)]; low holotranscobalamin [4.1 (2.0–8.7)], high methylmalonic acid [3.5 (1.8–7.1)], high homocysteine [4.8 (2.3–10.0)] and low wellness score [5.1 (2.61–10.46)]. After correction for relevant covariates, cognitive impairment remained significantly associated with high homocysteine [4.85 (2.24–10.53)] and with a low wellness score [5.60 (2.61–12.01)] but not with transcobalamin, haptocorrin, or analogs on haptocorrin. CONCLUSIONS Cognitive impairment was associated with the combined effects of the 4 biomarkers of vitamin B12 deficiency when included in a wellness score but was not associated with binding proteins or analogs on haptocorrin.


2004 ◽  
Vol 171 (4S) ◽  
pp. 15-15
Author(s):  
Urs E. Studer ◽  
Richard Aebischer ◽  
Katharina Ochsner ◽  
Werner W. Hochreiter

Sign in / Sign up

Export Citation Format

Share Document